BofA/Merrill Lynch Upgrades Edwards Lifesciences (EW) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Edwards Lifesciences Reports Second Quarter Results
July 26, 2016 4:15 PM EDTIRVINE, Calif., July 26, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2016.
Second Quarter Highlights:
Sales grew 23.1% to $759.3 million; underlying1 sales were up 21% Global Transcatheter Heart Valve Therapy (THVT) sales grew 48.7%; underlying grew 45% U.S. THVT sales were up 71.5%; underlying grew 66% GAAP EPS was $0.58, an increase of 13.7%; adjusted2 EPS grew 33% to $0.76 2016... More